Cefoxitin is a beta-lactam, second-generation cephalosporin antibiotic with bactericidal activity.

Cefoselis sulfate

Cefmenoxime hydrochloride is a third-generation cephalosporin antibiotic.

Cefetamet pivoxil hydrochloride is an oral third generation cephalosporin antibiotic.

Cefditoren pivoxil

Cefdinir (Omnicef)

CE-245677 is a potent, selective, orally active, dual Tie2/Trk kinase inhibitor with IC50 of 4.7 nM, 1 nM for Tie2 and TrkA/B, respectively.

CE-224535 (PF-04905428) is a potent and selective P2X7 receptor antagonist with IC50 of 1.4 nM (inhibition of the release of lL-1b from monocytes stimulated by ATP).

CDP-840 (CDP840.

CDP-840 (CDP840.

CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection.

CDK5 inhibitor 20-223 (CP 668863) potent, selective, ATP-competitive CDK2/5 inhibitor with IC50 of 6.0 and 8.8 nM for CDK2/CyclinE and CDK5/p35, with little to no activity against CDK1/4/6/7/9.

CDK12 inhibitor E9 S-isomer (E9, CDK12-IN-E9) is a clinical analog of THZ1 and a selective, covalent CDK12 inhibitor that is not susceptible to ABC transporter-mediated drug efflux.

CDK12 inhibitor 2 is a potent, selective, non-covalent CDK12 inhibitor with IC50 of 52 nM, displays >192-fold selectivity over CDK2/7/8/9.

CDD-450 is an unique inhibitor that selectively blocks p38α activation of proinflammatory kinase MAPK-MK2 while sparing p38α activation of PRAK and ATF2.

CDD3506 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity.

CDD3505 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity.

Cdc7 inhibitor is a potent inhibitor of Cdc7 kinase with pIC50 of 10.01 against CDC7/DBF4 in TR-FRET assays..

Cdc25 inhibitor S8 is an anti-fungal small molecule that inhibits cdc25 phosphatase with Ki of 140 uM.

CD12681 (CD-12681) is a potent, selective RORγ inverse agonist with IC50 of 19 nM, displays no activity against a panel of nuclear receptors (RORα, RARγ, LXRβ, PPARγ and VDR).

CCX-354 (GSK-2941266, CCX354-C, CCX354) is a potent, selective, orally-available CCR1 antagonist for the treatment of inflammatory diseases such as rheumatoid arthritis (RA)..

CCX140 is a potent CCR2 antagonist.

CCT251921 is a potent, selective, and orally bioavailable small-molecule modulators of the mediator complex-associated kinases CDK8 and CDK19. (IC50 data: CDK8:=2.3 nM; CDK19 = 2.6 nM).

CCT241533 Hcl is a potent serine/threonine checkpoint kinase (Chk2) inhibitor with IC50 of 3 nM; shows minimal cross-reactivity against a panel of kinases at 1 uM.

CCT241161 is a potent pan-RAF inhibitor with IC50 of 30, 15 and 6 nM for BRAF, V600E-BRAF and C-RAF, also potently inhibits SRC and LCK (IC50=10 and 3 nM, respectively)..

CCT128930 is a potent, selective, ATP-competitive AKT inhibitor with IC50 of 6 nM (AKT2), 28-fold selectivity over the closely related PKA.

CCT-031374 is a selective β-catenin signaling inhibitor with IC50 of 6.1 uM.

CCT020312 is capable of delivering potent, and eukaryotic initiation factor 2-alpha kinase 3 (EIF2AK3) selective, proliferation control and also is an activator of RNA-like endoplasmic reticulum kinase (PERK).

CCT-01815 is a novel potent inhibitor of Hsp90 ATPase activity with IC50 of 7.1 uM.

CCT 365623(CCT365623, CCT-365623) is a potent, orally active small molecule inhibitor of lysyl oxidase (LOX) with IC50 of 0.89 uM.